AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company, has named Dr. R. Todd Plott, M.D., a board-certified dermatologist with over 30 years of clinical experience and former FDA advisory committee member, to its Board of Directors. This strategic appointment coincides with the advancement of Phio's lead candidate PH-762, an investigational therapy targeting cutaneous squamous cell carcinoma and other skin cancers, developed using the company’s proprietary INTASYL gene silencing technology. Dr. Plott’s extensive expertise in dermatologic research, drug development, and FDA regulatory affairs is expected to guide Phio’s regulatory and clinical milestones for PH-762.
Key Points
- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) appoints Dr. R. Todd Plott, M.D. to its Board of Directors
- Dr. Plott is a board-certified dermatologist with more than 30 years of experience in dermatologic care and pharmaceutical innovation
- He served on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021
- Phio is progressing PH-762, an INTASYL compound designed to silence the PD-1 gene, for treating skin cancers including squamous cell carcinoma, melanoma, and Merkel cell carcinoma
Board Gains Dermatology and FDA Regulatory Expertise with Dr. Plott
Dr. R. Todd Plott brings valuable regulatory and clinical development experience to Phio’s Board of Directors. As a board-certified dermatologist with over three decades dedicated to advancing treatments for acne, skin disorders, and skin cancers through pharmaceutical research and development, Dr. Plott has overseen hundreds of clinical trials. His expertise spans clinical trial design, execution, and regulatory compliance.
His tenure on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021 highlights his leadership in dermatology and deep understanding of regulatory pathways for skin disease therapies. Currently practicing privately with a focus on complex skin diseases, acne, and skin cancer, Dr. Plott’s combined FDA advisory experience and clinical trial oversight make him a strategic asset for Phio as it develops innovative skin cancer treatments.
PH-762 Clinical Program Targets Multiple Skin Cancer Indications
Phio’s lead clinical program centers on PH-762, an INTASYL compound engineered to silence the PD-1 gene implicated in various skin cancers. PH-762 aims to boost the immune system’s ability to eliminate cancer cells, representing a promising immunotherapeutic approach.
The ongoing Phase 1b clinical trial (NCT# 06014086) is evaluating PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Positioned as a potential non-surgical treatment option, PH-762’s development aligns closely with Dr. Plott’s dermatology expertise and clinical trial experience, which are expected to inform Phio’s regulatory strategy and clinical advancement.
INTASYL Platform and Mechanism of Action
Phio’s proprietary INTASYL siRNA gene silencing platform underpins its therapeutic approach. INTASYL compounds are designed to enhance immune cell function to more effectively target and destroy cancer cells by silencing specific genes such as PD-1, thereby improving anti-tumor immune responses.
As a clinical-stage biopharmaceutical company, Phio focuses on advancing candidates through human trials rather than commercialization. PH-762 serves as the flagship program demonstrating INTASYL’s potential in oncology. Dr. Plott’s board appointment reflects Phio’s intent to bolster governance and strategic guidance amid regulatory and clinical development activities.
CEO Robert Bitterman Highlights Strategic Value of Appointment
Robert Bitterman, Phio’s CEO and Chairman, stated, "Dr. Plott's exceptional experience in dermatology and clinical development provides a valuable resource as we advance PH-762 for squamous cell carcinoma." This underscores the company’s focus on leveraging Dr. Plott’s combined clinical and regulatory expertise to support its near-term clinical priorities.
The announcement does not specify changes in board composition, size, or the duration of Dr. Plott’s term.
Clinical and Regulatory Outlook
While no specific timelines for regulatory submissions or clinical milestones were disclosed, Phio continues to progress PH-762 through a Phase 1b trial across multiple skin cancer indications. Dr. Plott’s extensive experience overseeing clinical trials positions him to contribute significantly to Phio’s clinical development strategy.
His FDA advisory committee background suggests Phio is preparing for upcoming regulatory interactions, although no details on FDA submissions or meetings were provided. Investors will likely monitor future updates on clinical study designs and regulatory engagement.
Dermatology Expertise Enhances Market Relevance
Dr. Plott’s career in dermatology and pharmaceutical innovation in acne and skin conditions highlights his deep technical knowledge in the therapeutic areas relevant to PH-762. His role in advancing dermatologic medications through clinical and regulatory pathways complements Phio’s focus on novel skin cancer therapies.
His involvement in hundreds of clinical trials also indicates familiarity with complex study designs, which may benefit PH-762’s current Phase 1b multi-indication trial.
Board Governance and Strategic Implications
The announcement does not detail Dr. Plott’s board committee roles, whether he replaces a prior director, or if the board size has changed. Investors seeking comprehensive governance information should refer to Phio’s upcoming proxy statements or SEC filings.
The timing of this appointment during active Phase 1b studies suggests Phio is positioning for accelerated development decisions. Dr. Plott’s FDA advisory and clinical trial expertise may be instrumental as the company evaluates next steps post-trial completion or interim analyses.
About Phio Pharmaceuticals
Headquartered in King of Prussia, Pennsylvania, Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company advancing the INTASYL siRNA gene silencing platform with a focus on oncology. Its therapeutic strategy targets cancer by modulating immune function through targeted gene silencing. The company’s lead program, PH-762, is in clinical evaluation for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
As a NASDAQ-listed clinical-stage company, Phio complies with U.S. Securities and Exchange Commission reporting requirements. The announcement includes forward-looking statements regarding FDA interactions, clinical timelines, manufacturing, and capital. Investors are advised to review the company’s latest Form 10-K and Form 10-Q filings for detailed risk disclosures.
Forward-Looking Statements and Risk Factors
The release contains standard forward-looking disclaimers noting that actual outcomes may differ materially from expectations. Factors influencing the business include FDA regulatory impacts, inflation, economic conditions, clinical results, regulatory timing, commercialization success, manufacturing capabilities, intellectual property protection, and financing access.
No quantitative guidance on development timelines, revenue, or capital needs was provided. The company does not commit to updating forward-looking statements except as required by law. Investors should consult SEC filings for comprehensive risk information before making investment decisions based on this announcement or other disclosures.
